Type 1 Diabetes
An opportunity to improve patient care
We believe early identification of Type 1 Diabetes can significantly improve patient care—and Labcorp can provide the answers you need.
T1D is an autoimmune disease characterized by the body’s attack on pancreatic β-cells that eventually leads to inability to produce insulin. As a result, T1D can progress silently—for months or even years before the onset of symptoms. Patients at-risk for clinical T1D may not be aware of their condition, which is often associated with family history and genetic factors.
Research shows that at least 1.6 million people in the U.S. 1(18 million globally) live with T1D, and the prevalence is increasing. Another estimated 300K people are at increased risk2 of clinical T1D in the U.S.
After Diagnosis: What’s Next?
There are no currently approved treatments to delay symptom onset for patients. It can be helpful after diagnosis to have a discussion with your patient about how to prevent DKA and how to manage T1D complications.
Your T1D patients can be at risk for other autoimmune diseases, therefore, it may be beneficial to screen for thyroid disease soon after T1D diagnosis and every one to two years thereafter, or sooner if symptoms present. Screening for celiac disease is also recommended when gastrointestinal symptoms exist, or laboratory manifestations suggestive of celiac disease are present.6
Patient Resource Groups
We recommend connecting your T1D patients with many active resource groups online—such as JDRF, Taking Control of your Diabetes (TCOYD) and Beyond Type 1—and encouraging your patients to consider upcoming or current clinical trials posted on TrialNet, as many promising studies are examining novel methods to delay the onset of T1D.
Labcorp Resources for Patients
We’re proud to be your laboratory service provider and want to help answer questions your patients may have, and help them navigate life with T1D. Send your patients to our new T1D resource center.
Together, let’s provide the best possible care for T1D patients.
NAFLD/NASH within Type 2 Diabetes patients
Type 2 diabetes increases the progression of NAFLD to the more serious condition of NASH, putting patients at a higher risk for cirrhosis and hepatocellular carcinoma. Beyond the impact to the liver, NAFLD has also been associated with an increase in other diabetic complications, including both micro- and macro-vascular complications. Patients may exhibit higher levels of insulinemia; they also may experience hyperglycemia that is difficult to control.
How will screening impact patient care? Many publications speak to the prevalence of NAFLD and NASH in type 2 diabetes and the importance of screening, including this recent article from Diabetes Care regarding screening and management of type 2 diabetic patients with NASH.
NAFLD/NASH within PCOS patients
Research shows Polycystic Ovary Syndrome (PCOS) patients, even those with a normal BMI, have an increased incidence of NAFLD, a potential NASH precursor.
PCOS is the most common endocrine disorder among reproductive-age women, affecting as many as 5 million US women. PCOS is increasingly being recognized as a lifelong metabolic disorder associated with obesity, insulin resistance, metabolic syndrome, and type 2 diabetes—all of which are risk factors for NAFLD. Furthermore, androgen excess may be a risk factor contributing to NAFLD.
Want to Learn More About NASH?
Non-alcoholic steatohepatits, or NASH, is a form of fatty liver disease. According to researchers, one in four people is affected by fatty liver disease, which can develop for a number of reasons.
There are an estimated 84 million adults 18 years and older in the U.S. who are prediabetic or at risk for developing diabetes.11 Prediabetes is characterized as higher than normal glucose levels but not high enough to meet criteria for diabetes.12
- Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services. 2020.
- Modeling the total economic value of novel type 1 diabetes (T1D) therapeutic concepts. JDRF T1D Fund; 2020.
- Diabetes symptoms. American Diabetes Association website. Accessed July 15, 2021. https://www.diabetes.org/diabetes/type-1/symptoms
- DKA (ketoacidosis) & ketones. American Diabetes Association website. Accessed July 15, 2021. https://www.diabetes.org/diabetes/complications/dka-ketoacidosis-ketones
- Screening can reduce DKA at onset by ≥50%. Provention Bio, Inc. website. Accessed July 15, 2021. https://connectedbyt1d.com/proactive-screening
- Classification and diagnosis of diabetes: standards of medical care in diabetes—2021 American Diabetes Association. Diabetes Care. Jan 2021, 44 (Supplement 1) S15-S33; DOI: 10.2337/dc21-S002
- Fieldwork research performed in January 2021 to survey 100 U.S. endocrinologists across private settings, community practices and academic centers.
- Simmons, KM, Steck, AK. Islet autoantibody testing. Current utility, future prospects in predicting and diagnosing type 1 diabetes. Clinical Laboratory News. 2017 Jul 1.
- Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104(43):17040-17045. doi:10.1073/pnas.070589410
- Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank.
- National Diabetes Statistics Report, 2017. National Center for Chronic Disease Prevention and Health Promotion, Center for Disease Control. Pages 1-20
- Standards of Medical Care in Diabetes Care – 2018. American Diabetes Association. Diabetes Care 2018;41:S1-S159